Open AccessTargeting of the diabetes prevention program leads to substantial benefits when capacity is constrained
Author(s) -
Natalia Olchanski,
David van Klaveren,
Joshua T. Cohen,
John B. Wong,
Robin Ruthazer,
David M. Kent
Publication year - 2021
Publication title -
acta diabetologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.141
H-Index - 67
eISSN - 1432-5233
pISSN - 0940-5429
DOI - 10.1007/s00592-021-01672-3
Subject(s) - diabetes mellitus , medicine , intensive care medicine , endocrinology
Approximately 84 million people in the USA have pre-diabetes, but only a fraction of them receive proven effective therapies to prevent type 2 diabetes. We estimated the value of prioritizing individuals at highest risk of progression to diabetes for treatment, compared to non-targeted treatment of individuals meeting inclusion criteria for the Diabetes Prevention Program (DPP).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom